This inventor holds 7 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Janssen Pharmaceuticals, Inc., Janssen Vaccines & Prevention B.v.. Active years: 2018-2023.
Location History:
- Leiden, NL (2018)
- Den Haag, NL (2019)
- The Hague, NL (2018 - 2023)
Company Filing History:
4 out of 161 
3 out of 117 
Years Active: 2018-2023
Title: Janik Adriaansen: Innovator in Vaccine Development
Introduction
Janik Adriaansen is a prominent inventor based in The Hague, Netherlands. He has made significant contributions to the field of vaccine development, holding a total of 7 patents. His work focuses on creating innovative solutions to combat infectious diseases.
Latest Patents
Among his latest patents is the ExPEC glycoconjugate vaccine formulation. This invention describes compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC). The multivalent vaccines he developed contain O-antigen polysaccharide covalently bound to an exotoxin A carrier protein, which can withstand multiple environmental stresses. Another notable patent involves adenovirus formulations, providing pharmaceutical adenovirus formulations, particularly liquid pharmaceutical formulations comprising adenoviruses.
Career Highlights
Janik has worked with reputable companies such as Janssen Pharmaceuticals, Inc. and Janssen Vaccines & Prevention B.V. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.
Collaborations
Janik has collaborated with notable professionals in his field, including Francesco Doro and Olga Labovitiadi. These partnerships have further enhanced his innovative work in vaccine development.
Conclusion
Janik Adriaansen is a key figure in the advancement of vaccine technology, with a strong portfolio of patents and a career dedicated to improving public health. His contributions continue to shape the future of immunization strategies.